Elicio Therapeutics (ELTX) Change in Accured Expenses (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Change in Accured Expenses data on file, last reported at -$602000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 77.24% year-over-year to -$602000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55000.0 (down 97.75% YoY) and the FY2025 annual result came in at -$2.0 million, down 142.68% from the prior year.
• Change in Accured Expenses eased to -$602000.0 in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.6 million in Q4 2024 to a low of -$2.6 million in Q1 2025.
• A 5-year average of $234058.8 and a median of -$179000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses soared 1541.13% — and 2025, when it slumped 512.27%.
• Tracing ELTX's Change in Accured Expenses over 5 years: stood at -$235000.0 in 2022, then surged by 230.21% to $306000.0 in 2023, then surged by 1064.38% to $3.6 million in 2024, then sank by 65.93% to $1.2 million in 2025, then slumped by 149.59% to -$602000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$602000.0 (Q1 2026), $1.2 million (Q4 2025), and $107000.0 (Q3 2025), per Business Quant data.